Stock Ratings / Health Care / SDGR / earnings

HRMY (80) AGIO (39) PRGO (41) VERA (35) ⌘ Pro Terminal →

Schrodinger Inc. (SDGR) Next Earnings Date & Expected ±12.5% Move

$29.99 -2.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Schrodinger Inc. (SDGR) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $2.24B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SDGR)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$3.75 Expected Swing

MODEL EARNINGS SETUP GAUGE

SDGR Quantitative Pre-Earnings Setup: 43/100

Trailing EPS: $4.25 • YoY Revenue Growth: 23.3%

Model Bullish Setup (43/100)Model Risk Weight (57/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$255.9M	-$103.3M	$12.5M	55.7%
FY 2024	2024-12-31	$207.5M	-$187.1M	-$164.7M	63.6%
FY 2023	2023-12-31	$216.7M	$40.7M	-$136.7M	55.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SDGR)

✓Walkthrough of SDGR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SDGR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +150.75%▲ ASCENDING CHANNEL

2026-10-30O $29.00H $29.99L $26.41C $29.99VOL 1.95M

RES: $37.30SUP: $19.00SMA50: $24.96SMA200: $16.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SDGR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SDGR Butterfly Map → + Track SDGR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +23.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SDGR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SDGR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SDGR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SDGR)

Health Care Rank #538 of 1016 ⚔️ HRMY vs SDGR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SDGR vs. HRMY, AGIO, PRGO, VERA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Schrodinger Inc. (SDGR) ranks #538 by composite RQD confidence (43/100, grade D-) and #240 by equity capitalization ($2.24B). Within this direct 5-issuer industry benchmark cohort, HRMY leads on earnings valuation at 14.2x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with SDGR at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SDGR ACTIVE Schrodinger Inc.	D-	43/100	—	55.7%	-35.0%	-2.85%	$2.24B	Benchmark Subject
HRMY Harmony Biosciences Holdings Inc.	B+	80/100	14.2x	77.2%	63.0%	+0.23%	$2.25B	/hrmy-vs-sdgr →
AGIO Agios Pharmaceuticals Inc.	D-	39/100	—	88.3%	-33.8%	-2.33%	$2.22B	/agio-vs-sdgr →
PRGO Perrigo Company plc	D-	41/100	—	35.1%	-13.6%	-0.13%	$2.21B	/prgo-vs-sdgr →
VERA Vera Therapeutics Inc. (Class A)	D-	35/100	—	—	-35.0%	-1.32%	$2.20B	/vera-vs-sdgr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001490978

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Schrodinger Inc. (SDGR) reported GAAP revenue of $255.9M (+23.3% vs. FY2024 revenue of $207.5M , and +18.1% cumulative change since FY2023) , GAAP net income of -$103.3M, operating cash flow of $13.9M, and free cash flow of $12.5M (+107.6% YoY). On the balance sheet, SDGR closed FY2025 with $726.2M in total assets against $0 in total debt (Altman Z-Score: 2.64, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$255.9M	-$103.3M	$13.9M	$12.5M	$726.2M	—
FY2024 (FY)	2024-12-31	$207.5M	-$187.1M	-$157.4M	-$164.7M	$823.2M	—
FY2023 (FY)	2023-12-31	$216.7M	$40.7M	-$136.7M	-$136.7M	—	—

3. SDGR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SDGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Schrodinger Inc. (NASDAQ: SDGR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $29.99 (-2.85% 1D, market cap $2.24B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, SDGR ranks #538 in composite RQD confidence.

How does SDGR compare to HRMY and AGIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SDGR carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 55.7%, and ROIC of -35.0%. By comparison, HRMY (Harmony Biosciences Holdings Inc.) holds a B+ grade (80/100 RQD, P/E 14.2x, ROIC 63.0%, cap $2.25B) and AGIO (Agios Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.8%, cap $2.22B). Among the 5-stock peer group, HRMY leads on earnings multiple (14.2x) while HRMY leads on capital efficiency (63.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SDGR?

Per SDGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001490978), Schrodinger Inc. generated $255.9M in revenue (+23.3% YoY), -$103.3M in net income, and $12.5M in free cash flow against $726.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SDGR trading relative to its 50-day, 200-day, and 52-week technical levels?

SDGR last traded at $29.99 (-2.85% on volume of 1,364,952 shares), positioning the stock +20.15% above its 50-day simple moving average ($24.96) and +78.94% above its 200-day simple moving average ($16.76). Across its 52-week range of $10.95 to $33.78, SDGR sits at the 83.4% percentile with a 14-day RSI of 53.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($26.24 to $33.74).